A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

Trial Profile

A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Terameprocol (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Erimos Pharmaceuticals
  • Most Recent Events

    • 20 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 24 Apr 2008 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top